“Cancer chemotherapeutics have become more complex and more expensive in the attempt to move away from ‘one size fits all’ therapies, to truly personalised therapies. To mitigate the cost of those therapeutics, we need to standardise our decision-making tools about optimal patient treatments, which will lead to better patient outcomes and a reduction in wasted drug costs.”

Read the article here.